Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AIR-CF4: Aztreonam Lysine for Inhalation in Cystic Fibrosis with Mild Lung Disease and Pseudomonas aeruginosa
2015-000395-97Phase 3
- Sponsor
- Gilead Sciences
- Start
- Feb 2015
- Modality
- Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in cystic fibrosis (CF) comparing Aztreonam lysine for inhalation with Placebo inhalation (2 arms). Primary endpoint: Change from baseline at Day 28 in clinical respiratory symptoms.
02
Drugs
aztreonam
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on 2015-000395-97.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-000395-97.